Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis.
Rheumatoid arthritis (RA) is the most common systemic autoimmune disease characterized by articular and extra-articular manifestations involving cardiovascular (CV) diseases. RA increases the CV mortality by up to 50 % compared with the global population and CV disease is the leading cause of death in patients with RA. There is growing evidence that RA favors accelerated atherogenesis secondary to endothelial dysfunction (ED) that occurs early in the course of the disease. ED is a functional and reversible alteration of endothelial cells, leading to a shift of the actions of the endothelium towards reduced vasodilation, proinflammatory state, proliferative and prothrombotic properties. The mechanistic links between RA and ED have not been fully explained, but growing evidence suggests a role for traditional CV factors, auto-antibodies, genetic factors, oxidative stress, inflammation and iatrogenic interventions such as glucocorticoids (GCs) use. GCs have been used in RA for several decades. Whilst their deleterious CV side effects were described in the 1950s, their effect on CV risk associated with inflammatory arthritis remains subject for debate. GC might induce negative effects on endothelial function, via a direct effect on endothelium or via increasing CV risk factors. Conversely, they might actually improve endothelial function by decreasing systemic and/or vascular inflammation. The present review summarizes the available data on the impact of GCs on endothelial function, both in normal and inflammatory conditions, with a special focus on RA patients.
EA 4267 FDE, FHU INCREASE, Université Bourgogne Franche-Comté, F-25030, Besancon, France.|Service de Rhumatologie, CHRU Besançon, F-25030, Besançon, France.
Frank
F
Verhoeven
EA 4267 FDE, FHU INCREASE, Université Bourgogne Franche-Comté, F-25030, Besancon, France.|Service de Rhumatologie, CHRU Besançon, F-25030, Besançon, France.
Clément
C
Prati
EA 4267 FDE, FHU INCREASE, Université Bourgogne Franche-Comté, F-25030, Besancon, France.
Katy
K
Maguin-Gaté
Service de Rhumatologie, CHRU Besançon, F-25030, Besançon, France.|EA 4266, Université Bourgogne Franche-Comté, F-25030, Besancon, France.
Daniel
D
Wendling
EA 4267 FDE, FHU INCREASE, Université Bourgogne Franche-Comté, F-25030, Besancon, France. cdemouge@univ-fcomte.fr.
Céline
C
Demougeot
D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000209:etiology*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000473:pathology; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans
D018501:Antirheumatic Agents; D005938:Glucocorticoids
Endothelial function; Glucocorticoids; Rheumatoid arthritis